Gilead Sciences Unusual Options Activity - Gilead Sciences (NASDAQ:GILD)
Corus Pharma Arresto Biosciences Gilead Sciences Call Experts Say On Gilead Sciences Volume Open Interest Development Morgan Stanley
Source: benzinga.com
📰 Corus Pharma News
Corus Pharma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Corus Pharma. Real-time updates on events, politics, business and more.
8 Undervalued Quality Healthcare Stocks
These wide-moat healthcare stocks are trading below their fair value estimates.
Source: morningstar.com
Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks
A majority of the top 10 dividend-yielding names are undervalued.
Source: morningstar.com
Top 10 Holdings of Our Ultimate Stock-Pickers' Index
We examine the biggest contributors to--and detractors from--the performance of the index during the past year.
Source: morningstar.com
Gilead Sciences, Inc. (NASDAQ:GILD) - Recap: Gilead Sciences Q1 Earnings
52-week low: $56.56 Company Description Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gileads acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination dru...
Source: benzinga.com